Lindbrook Capital’s Innoviva INVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$5.8K Buy
320
+68
+27% +$1.22K ﹤0.01% 1898
2024
Q4
$4.37K Buy
252
+32
+15% +$614 ﹤0.01% 2044
2024
Q3
$4.25K Sell
220
-92
-29% -$1.7K ﹤0.01% 2075
2024
Q2
$5.12K Buy
312
+4
+1% +$62 ﹤0.01% 1981
2024
Q1
$4.69K Hold
308
﹤0.01% 1921
2023
Q4
$4.94K Hold
308
﹤0.01% 1896
2023
Q3
$4K Sell
308
-97
-24% -$1.26K ﹤0.01% 1861
2023
Q2
$5.16K Buy
405
+217
+115% +$2.72K ﹤0.01% 1792
2023
Q1
$2.12K Buy
188
+91
+94% +$1.1K ﹤0.01% 2222
2022
Q4
$1.28K Sell
97
-876
-90% -$11.5K ﹤0.01% 2404
2022
Q3
$11K Buy
973
+80
+9% +$1.1K ﹤0.01% 1280
2022
Q2
$13K Buy
+893
New +$14.6K ﹤0.01% 1143

Other funds holding INVA

Lindbrook Capital's INVA Position: Q1 2025 in Review

Lindbrook Capital increased its Innoviva (INVA) stake by 27% in Q1 2025, buying an estimated $1.22K and bringing the position to 320 shares worth $5.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1898.

Lindbrook Capital first reported a position in INVA in Q2 2022 and has held it in 12 quarters since. The position peaked at $13K in Q2 2022. 246 funds tracked by Wall St. Rank hold INVA as of Q1 2025.

  • Lindbrook Capital held 320 shares of Innoviva worth $5.8K as of Q1 2025.
  • Lindbrook Capital bought 68 Innoviva shares in Q1 2025, an estimated $1.22K.
  • Innoviva made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1898 holding.
  • Lindbrook Capital first reported a position in Innoviva in Q2 2022 and has held it in 12 quarters since.
  • Lindbrook Capital's Innoviva position peaked at $13K in Q2 2022.
  • 246 funds tracked by Wall St. Rank held Innoviva as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.